Stanley Jacot - Arcadia Biosciences CEO President

RKDA Stock  USD 1.96  0.03  1.51%   

CEO

Stanley Jacot is CEO President of Arcadia Biosciences
Age 53
Address 5950 Sherry Lane, Dallas, TX, United States, 75225
Phone214 974 8921
Webhttps://www.arcadiabio.com

Arcadia Biosciences Management Efficiency

The company has return on total asset (ROA) of (0.345) % which means that it has lost $0.345 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7836) %, meaning that it created substantial loss on money invested by shareholders. Arcadia Biosciences' management efficiency ratios could be used to measure how well Arcadia Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. As of May 5, 2024, Return On Tangible Assets is expected to decline to -0.75. In addition to that, Return On Capital Employed is expected to decline to -0.9. At present, Arcadia Biosciences' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 5.5 M, whereas Non Currrent Assets Other are forecasted to decline to about 2.5 M.
The company currently holds 1.01 M in liabilities with Debt to Equity (D/E) ratio of 0.09, which may suggest the company is not taking enough advantage from borrowing. Arcadia Biosciences has a current ratio of 6.21, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Arcadia Biosciences until it has trouble settling it off, either with new capital or with free cash flow. So, Arcadia Biosciences' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Arcadia Biosciences sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Arcadia to invest in growth at high rates of return. When we think about Arcadia Biosciences' use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 3 records

CEO Age

Darren MintonSmart for Life
42
Jason ViethLaird SuperfoodInc
50
Yefang ZhangFarmmi Inc
57
Arcadia Biosciences, Inc. produces and markets plant-based health and wellness products in the United States. The company was incorporated in 2002 and is headquartered in Davis, California. Arcadia Bio operates under Agricultural Inputs classification in the United States and is traded on NASDAQ Exchange. It employs 58 people. Arcadia Biosciences (RKDA) is traded on NASDAQ Exchange in USA. It is located in 5950 Sherry Lane, Dallas, TX, United States, 75225 and employs 21 people. Arcadia Biosciences is listed under Agricultural Products & Services category by Fama And French industry classification.

Management Performance

Arcadia Biosciences Leadership Team

Elected by the shareholders, the Arcadia Biosciences' board of directors comprises two types of representatives: Arcadia Biosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Arcadia. The board's role is to monitor Arcadia Biosciences' management team and ensure that shareholders' interests are well served. Arcadia Biosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Arcadia Biosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
Belinda Yao, VP Operations
Stanley Jacot, CEO President
Brian Schaffer, Senior Sales
Kevin Hodges, VP Operations
Thomas Schaefer, CFO Secretary
Tracy Baker, Senior Operations
Pamela Haley, CFO Sec
Laura Pitlik, Chief Officer

Arcadia Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Arcadia Biosciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Currently Active Assets on Macroaxis

When determining whether Arcadia Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Arcadia Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Arcadia Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Arcadia Biosciences Stock:
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Arcadia Biosciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment.
For information on how to trade Arcadia Stock refer to our How to Trade Arcadia Stock guide.
Note that the Arcadia Biosciences information on this page should be used as a complementary analysis to other Arcadia Biosciences' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.

Complementary Tools for Arcadia Stock analysis

When running Arcadia Biosciences' price analysis, check to measure Arcadia Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcadia Biosciences is operating at the current time. Most of Arcadia Biosciences' value examination focuses on studying past and present price action to predict the probability of Arcadia Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcadia Biosciences' price. Additionally, you may evaluate how the addition of Arcadia Biosciences to your portfolios can decrease your overall portfolio volatility.
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Is Arcadia Biosciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Arcadia Biosciences. If investors know Arcadia will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Arcadia Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.63)
Earnings Share
(10.64)
Revenue Per Share
4.309
Quarterly Revenue Growth
0.573
Return On Assets
(0.34)
The market value of Arcadia Biosciences is measured differently than its book value, which is the value of Arcadia that is recorded on the company's balance sheet. Investors also form their own opinion of Arcadia Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Arcadia Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Arcadia Biosciences' market value can be influenced by many factors that don't directly affect Arcadia Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Arcadia Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Arcadia Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Arcadia Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.